Clinical trial

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

NCT07128251

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-08-20

PhasePHASE2

Study timeline

Study start (estimated)2025-08-20Date precision: day

Registry last updated2025-08-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hepatocellular Carcinoma (HCC)unresolved

Immunotherapyunresolved

PD-1unresolved

CTLA-4unresolved

TACEunresolved

Interventions

TACE treatmentPROCEDURE

Iparomlimab and Tuvonralimab Injection (QL1706)DRUG

BevacizumabDRUG · verified · RxNorm: bevacizumab

Sponsors & collaborators

Anhui Provincial Hospitallead sponsor

Qilu Hospital of Shandong Universitycollaborator

Henan Provincial People's Hospitalcollaborator

First Affiliated Hospital of Guangxi Medical Universitycollaborator

Shanxi Province Cancer Hospitalcollaborator

Xi'an International Medical Center Hospitalcollaborator

The Second Affiliated Hospital of Harbin Medical Universitycollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07128251 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.